International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 299-308 www.ijprajournal.com ISSN: 2456-4494

"Integrative Oncology: Uniting Herbal and Allopathic Medicine for Cancer Management"

Dr.Nithya PV*[1], Dr. Jojymol.K.Joy[2], Dr.Athulya jayakrishnan[3]

[1]*Department Of Pharmacy Practice, Sri Raghavendra College Of Pharmacy,Rajiv Gandhi University Of Health Sciences, Byrati Extension, HennurBagalur Main Road, Kothanur, Bangalore -560077*

[21]*Department Of Pharmacology , Sri Raghavendra College Of Pharmacy,Rajiv Gandhi University Of Health Sciences, Byrati Extension, HennurBagalur Main Road, Kothanur, Bangalore -560077*

[3]*Department Of Pharmacology, Sri Raghavendra College Of Pharmacy,Rajiv Gandhi University Of Health Sciences, Byrati Extension, HennurBagalur Main Road, Kothanur, Bangalore -560077*

Date of Submission: 10-03-2025 Date of Acceptance: 20-03-2025

ABSTRACT:

Cancer continues to be a major public health issue worldwide, with rising incidence and mortality. Although allopathic modalities such as chemotherapy, radiotherapy, immunotherapy, and targeted therapy have greatly enhanced survival, their limitations such as toxicity, drug resistance, and economic constraints underscore the necessity for integrative oncology. Integrative oncology blends standard therapies with complementary herbal medicine to maximize therapeutic benefits and minimize side effects. Traditional medicinal systems-based herbal medicine holds bioactive molecules that have anticancer activities, including apoptosis induction, angiogenesis suppression, and immunomodulation. The main herbal compounds are curcumin, resveratrol, quercetin, epigallocatechingallate, berberine, withaferin A, and sulforaphane, all of which prove to be effective in augmenting the standard treatments as well as decreasing their toxicities. Comparative research proves that integrative oncology can enhance survival and decrease chemotherapy-induced toxicity. Meta-analysis of 14 clinical trials identified that the combination of herbal and standard treatments decreased risk of mortality and side effects of treatment, although studies caution against replacing usual care with alternative medicine alone. Although promising, integrative oncology is hampered by inconsistent regulation, few clinical trials, and herb-drug interaction concerns. Large-scale clinical trials in the future are needed to confirm the efficacy and safety of herbal therapy combined with conventional therapy. An evidence-based, patient-centered approach combining both modalities may provide the most effective and safest cancer management approach. This review emphasizes the need for concerted oncological care, promoting concerted collaboration of scientifically substantiated herbal medicine with mainstream treatment to enhance patient outcome.

Keywords: Oncology, herbal medicine, allopathic medicine, chemotherapy, radiotherapy, immunotherapy, targeted therapy.

I. INTRODUCTION:

Cancer continues to be among the most insurmountable health issues globally, with rising incidence and mortality. The World Health Organization (WHO) estimates that cancer caused approximately 10 million deaths in 2020 and ranks as one of the major causes of mortality worldwide (1). The burden of the disease persists amid factors influencing population aging, lifestyle, and the environment. Traditional treatment regimens, such as chemotherapy, radiotherapy, immunotherapy, targeted therapy, and hormone therapy, have greatly enhanced survival and disease control rates (2). Yet, these treatment methods have serious side effects, such as major toxicities, drug resistance, expense, and compromised patient quality of life (3). In addition, access and cost barriers restrict the dissemination of these treatments, particularly to low- and middle-income countries, perpetuating inequalities in the treatment and outcome of cancer.In view of these restrictions, integrative oncology has developed as an optimistic strategy with a vision of synergizing mainstream cancer therapies with supplementary treatments like herbal medicine in order to optimize treatment efficacy at lower side effects (4). Integrative oncology recognizes the potential of traditional healing systems, such as Ayurveda, Traditional Chinese Medicine (TCM), and other native practices, that have employed medicinal plants for millennia to cure multiple diseases, including cancer (5). Herbal medicine, which includes bioactive agents with anticancer activity, act through various mechanisms like induction of apoptosis, suppression of

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 299-308 www.ijprajournal.com ISSN: 2456-4494

angiogenesis, immune system modulation, and augmentation of efficacy of conventional treatment. Emerging evidence indicates that the integration of herbal medicine with conventional cancer therapies has the ability to counteract chemotherapy-induced toxicity, inhibit drug resistance, and enhance the well-being of patients (6).The acceptance of herbal medicine into mainstream oncology has been gaining momentum from scientific research illustrating its ability to complement conventional therapies. A few plant-derived agents, including paclitaxel (Taxol) of the Pacific yew tree and vincristine of the Madagascar periwinkle, have been effectively integrated into standard cancer therapy (7). Moreover, phytochemicals like curcumin, resveratrol, and quercetin have shown considerable anticancer activity in preclinical and clinical research, augmenting the action of chemotherapy and radiotherapy and reducing their toxicity (8, 9). However, for all these promising results, reservations persist regarding insufficient standardized dosing, risk of herb-drug interactions, and the requirement of further broad-scale clinical testing prior to adoption.This review proposes to discuss the synergistic value of an integrated approach using herbal and allopathic treatment for cancer therapy. It will offer a comparison of both the treatment modalities, explain their mechanisms of action, outline their strengths and limitations, and evaluate clinical evidence favoring integrative oncology. Through a careful review of existing research, the review aims to contribute to the developing discipline of integrative cancer care, and promote an evidence-based integration of herbal medicine with oncology. Future directions for research and clinical use will also be addressed to advance safer and more effective treatment strategies that maximize patient benefits.



Allopathic Cancer Therapies:

1. Chemotherapy

Chemotherapy is a systemic therapy that employs cytotoxic agents to attack actively dividing cancer cells. It primarily functions by disrupting the DNA replication and cell division process, which results in apoptosis or cell death (11). Chemotherapeutic agents are categorized according to their mode of action. Alkylating agents, including cyclophosphamide and cisplatin, cause DNA cross-links, inhibiting replication and transcription, eventually initiating apoptosis (12). Antimetabolites, like 5-fluorouracil and methotrexate, are similar to natural nucleotides and interfere with DNA synthesis and arrest cell cycle Mitotic inhibitors, like paclitaxel and vincristine, inhibit microtubule activity, causing proper segregation of the chromosomes and resulting in cell cycle arrest (13). Though it is effective, chemotherapy is not selective and influences both the malignant and normal dividing cells, causing severe side effects like myelosuppression, gastrointestinal toxicity, and organ injury.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 299-308 www.ijprajournal.com ISSN: 2456-4494

2**. Radiation Therapy**

Fig 1: Radiation Therapy

Radiation therapy applies high-energy ionizing radiation to destroy cancer cells by causing DNA damage, mostly double-strand breaks. The damage causes cell cycle arrest and apoptosis, which inhibits tumor growth (14). Radiation therapy is administered by multiple techniques, such as external beam radiation therapy (EBRT), where targeted radiation doses are aimed at tumors, and brachytherapy, in which radioactive materials are inserted inside or in proximity to the tumor (15). Radiation therapy effectiveness relies on selective destruction of malignant tissue and avoidance of neighboring normal tissue. Nevertheless, radiation may also harm nearby normal tissues, which causes side effects like fibrosis, second malignancies, and organ dysfunction induced by radiation. Technologies like intensity-modulated radiation therapy (IMRT) and proton therapy have facilitated high precision, minimizing collateral damage and improving treatment outcomes (16).

3**. Immunotherapy**

Immunotherapy is a groundbreaking treatment that utilizes the immune system of the body to identify and target cancer cells for destruction. One of the best immunotherapy modalities is immune checkpoint blockade targeting inhibitory receptors like programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (Pardoll, 2012). Checkpoint inhibitors like pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4) increase T-cell activation and antitumor immunity (Sharma & Allison, 2015). The current other major immunotherapy strategy is chimeric antigen receptor (CAR) T-cell therapy, in which patient T cells are engineered to produce receptors that can specifically recognize tumor-associated antigens (17). Immunotherapy has been very successful for cancers like melanoma and non-small cell lung cancer but has varied efficacy across patients and can result in immune-related adverse events (e.g., colitis, pneumonitis) that are challenging for clinicians to manage (18).

4. **Targeted Therapy**

Fig 2: Targeted Therapy

Targeted therapy aims to interfere with particular molecular pathways that are critical for the survival and growth of cancer cells. In contrast to conventional chemotherapy, targeted therapies specifically block oncogenic signaling with minimal harm to normal cells. Tyrosine kinase inhibitors (TKIs), e.g., imatinib, which inhibits the BCR-ABL fusion protein in chronic myeloid leukemia (CML) and thus prevents uncontrolled cell proliferation (19), represent one of the most important classes of targeted drugs. A second class consists of monoclonal antibodies, including trastuzumab, which is directed against the human epidermal growth factor receptor 2 (HER2) in breast cancer, inhibiting tumor growth. Although targeted therapies are more effective and less toxic, they are usually hampered by the emergence of drug resistance caused by genetic mutation and pathway redundancy (20, 21). Combination treatments and next-generation inhibitors are under investigation to counteract resistance and improve clinical results.

5. Hormone Therapy



Fig 3: Hormone Therapy

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 299-308 www.ijprajournal.com ISSN: 2456-4494

Endocrine therapy, otherwise referred to as hormone therapy, is applied for the treatment of hormone-receptor cancers like prostate and breast cancer. The endocrine therapy prevents the production of hormones or stops the receptors of hormones from blocking the growth of tumors (22). As an illustration, in estrogen receptor (ER) positive breast cancer, selective estrogen receptor modulators (SERMs) such as tamoxifen inhibit estrogen to bind to ERs, reducing the proliferation of cancer cells (23). Aromatase inhibitors (e.g., letrozole) suppress estrogen production, whereas androgen deprivation therapy (ADT) with medications such as leuprolide lowers testosterone levels in prostate cancer (24). Although effective, hormone therapy produces side effects like osteoporosis, cardiovascular disease, and metabolic alteration (25).

6. **Stem Cell Transplantation (Bone Marrow Transplant)**

Stem cell transplantation is commonly employed to reconstitute bone marrow function in individuals receiving high-dose chemotherapy or radiation therapy. It is most useful in the treatment of hematologic malignancies like leukemia, lymphoma, and multiple myeloma (26). The procedure entails infusing healthy hematopoietic stem cells from a donor (allogeneic transplant) or the patient's own (autologous transplant) to rebuild blood cells (27). However, allogeneic transplants are associated with the risks of graft-versus-host disease (GVHD), where donor immune cells reject the recipient's tissues and generate serious complications (28).

7. **Hyperthermia Therapy**



Fig 4:Hyperthermia Therapy

Hyperthermia treatment is the heating of cancer tissues to 40-45°C (104-113°F) to increase the efficacy of radiation therapy and chemotherapy (29). Heat kills cancer cells, causes apoptosis, and enhances tumor blood flow, which enhances drug delivery. Methods like microwave hyperthermia and radiofrequency ablation are applied to tumors in the liver, breast, and prostate (30). Although promising, hyperthermia therapy must be carefully controlled in terms of temperature to avoid harming nearby healthy tissues.

8**. Photodynamic Therapy (PDT**)

Photodynamic therapy is a cancer treatment that involves the use of light-sensitive medications (photosensitizers) and precise light wavelengths to produce reactive oxygen species that kill cancer cells (31). PDT is applied in the treatment of skin cancer, lung cancer, and esophageal cancer. One of its advantages is selective activation, which reduces damage to normal tissues. Nonetheless, PDT has several limitations, such as limited penetration of light into deep-seated tumors and hypersensitivity of the skin to sunlight following treatment (32).

Bioactive Herbal Compounds in Cancer Therapies:

Herbal medicine has been in use for thousands of years as an integral part of traditional health systems such as Ayurveda, Traditional Chinese Medicine (TCM), and indigenous systems of medicine to prevent and cure several diseases, including cancer. A number of plant-derived drugs have shown excellent anticancer potential, and these are now incorporated in contemporary oncology either as therapeutic agents directly or as adjuncts to orthodox therapy. The effectiveness of herbal medicine in cancer therapy is due to its varied bioactive compounds, which act on multiple pathways of tumor growth, drug resistance, and immune modulation.

1. Curcumin (Turmeric - Curcuma longa)

Fig 5: Turmeric - Curcuma longa

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 299-308 www.ijprajournal.com ISSN: 2456-4494

Curcumin, the polyphenolic molecule extracted from turmeric (Curcuma longa), is extensively researched for its anticancer activity. Curcumin has been shown to have anti-inflammatory, antioxidant, and anti-proliferative properties via the modulation of a variety of molecular targets, such as nuclear factor-kappa B (NF-κB), cyclooxygenase-2 (COX-2), and mitogen-activated protein kinase (MAPK) pathways. Curcumin causes apoptosis in cancer cells by increasing pro-apoptotic proteins like Bax and decreasing anti-apoptotic proteins like Bcl-2. It also inhibits angiogenesis by suppressing VEGF signaling, hence limiting tumor vascularization. Curcumin also increases chemotherapy potency and decreases drug resistance, and thus it is a good adjuvant in cancer treatment (33,34)

2. **Resveratrol (Grapes - Vitisvinifera)**

Fig 6: Grapes - Vitisvinifera

Resveratrol, a polyphenol that occurs naturally in grapes, berries, and peanuts, has shown anticancer activity of broad spectrum. It has its anticancer activity through various mechanisms, such as inhibition of proliferation, induction of apoptosis, and modulation of inflammatory and oxidative stress pathways. Resveratrol triggers tumor suppressor genes including p53 and disrupts oncogenic signaling pathways including phosphoinositide 3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR). It has also been found to improve the efficacy of chemotherapy and reduce its side effects, e.g., cardiotoxicity in doxorubicin therapy (35-37).

3. **Quercetin (Onion)**

Fig 7:Onion

Quercetin is a flavonoid present in onions, apples, and tea that is recognized for its strong antioxidant and anticancer properties. Quercetin causes apoptosis in cancer cells by modulating crucial apoptosis proteins like caspases and Bcl-2 family proteins. Quercetin also suppresses angiogenesis by downregulating VEGF and matrix metalloproteinases (MMPs), inhibiting metastasis and invasion of tumors. In addition, it has been known to modulate drug resistance by preventing efflux transporters like P-glycoprotein (P-gp), thus increasing the bioavailability and efficacy of chemotherapeutic agents (38-40).

4. **EpigallocatechinGallate (EGCG) (Camellia sinensis Green Tea)**

Fig 8:Camellia sinensis Green Tea

EGCG, the dominant catechin in green tea, possesses powerful anticancer activity due to its potential to suppress tumor growth and metastasis. It achieves this by suppressing oncogenic pathways like PI3K/Akt and Wnt/β-catenin while enhancing tumor suppressor pathways like p53. EGCG induces cell cycle arrest at the G1 phase, suppresses angiogenesis by downregulating VEGF expression, and boosts immune responses by regulating cytokine production. EGCG also synergizes with traditional

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 299-308 www.ijprajournal.com ISSN: 2456-4494

chemotherapy, increasing its efficacy while minimizing side effects such as oxidative stress(41-43)

5. Berberine (Barberry - Berberis vulgaris)

Fig 9:Barberry - Berberis vulgaris

Berberine, an alkaloid compound from Berberis vulgaris and other medicinal herbs, has been extensively investigated for its anticancer activity. It exerts its anticancer activity by causing apoptosis through mitochondrial damage and generation of reactive oxygen species (ROS). Berberine suppresses the PI3K/Akt/mTORsignaling pathway, suppressing cancer cell survival and growth. It also modulates immune functions by activating T-cells and suppressing tumor-induced immunosuppression. Berberine has also been reported to reverse multidrug resistance by suppressing ATP-binding cassette (ABC) transporters, which are responsible for chemotherapy resistance (44-47)

6. Withaferin A (Ashwagandha - Withaniasomnifera)

Fig 10: Ashwagandha - Withaniasom

Withaferin A, a steroidal lactone isolated from Withaniasomnifera (Ashwagandha), has exhibited significant anticancer activity. It promotes apoptosis by initiating the p53 pathway and blocking nuclear factor-kappa B (NF-κB), downregulating inflammation and survival of cancer cells. Withaferin A also blocks metastasis through downregulation of epithelial-mesenchymal transition (EMT)-associated proteins and suppression of tumorangiogenesis . It also increases the efficacy of chemotherapeutic drugs with the added advantage of sparing normal tissues from toxicity (48,49).

7. Sulforaphane (Broccoli - Brassica oleracea)

Fig 11:Broccoli - Brassica oleracea

Sulforaphane, a bioactive phytochemical present in broccoli and Brussels sprouts, belonging to the class of cruciferous vegetables, has been exhibited to possess highly effective anticancer activity. Its action is facilitated by the promotion of phase II detoxification enzymes, including glutathione S-transferase, which detoxifies carcinogens. Sulforaphanealso activates apoptosis by means of caspase activation and histone deacetylases (HDACs) inhibition, which participates in cancer progression (50, 51). Its capacity to boost immune responses and suppress chronic inflammation renders it a prospective agent in preventing and treating cancer.

Benefits of Herbal Remedies in Treating Cancer

1. Decreased Toxicity: In contrast to traditional therapies, herbal drugs selectively kill cancer cells without harming normal tissues, minimizing side effects like nausea, neuropathy, and immunosuppression.
2. Overcoming Drug Resistance: Several herbal compounds, including quercetin and berberine, are known to block drug efflux transporters, making chemotherapy more effective.
3. Synergistic Effects: Herbal medicines may be administered with mainstream therapies for increased potency and decreased dosages required, thus minimizing toxicity.
4. Immune Modulation: Several plant constituents enhance the immune system, boosting the body's power to fight cancer.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 299-308 www.ijprajournal.com ISSN: 2456-4494

Comparative Study of Allopathic and Herbal Medicine in Cancer Treatment;

Treatment of cancer involves a variety of therapeutic modalities, mainly classified as allopathic (conventional) medicine and herbal (alternative) medicine. Allopathic therapies like chemotherapy, radiation, and immunotherapy are supported by large-scale clinical trials and are the standard of treatment. They have notable side effects, however, such as immunosuppression, nausea, and fatigue. In contrast, herbal medicine has been reported to supplement conventional therapies by mitigating side effects, augmenting efficacy, and possibly circumventing drug resistance via bioactive compounds like flavonoids, polyphenols, and alkaloids. A Health Technology Assessment review of 14 clinical trials involving 1,965 cancer patients with breast, prostate, pancreatic, stomach, ovarian, and lung cancers revealed that combining herbal medicine with mainstream treatments lowered mortality risk (RR 0.67, 95% CI 0.51 to 0.90) and side effects of drugs (RR 0.62, 95% CI 0.54 to 0.71). This method raised healthcare expenditure by about $19.64 million annually. Another clinical trial enumerated the safety and potential activity of SH003, a herbal product, in the management of solid tumors, while Fucoidan exhibited anti-inflammatory and anti-cancer effects useful for advanced cancer patients.Although these advantages exist, research cautions against the use of only herbal or alternative therapy. A study by the National Cancer Institute found that cancer patients with breast, lung, or colorectal cancer who received only alternative therapy had lower survival rates. The breast and colorectal cancer patients were about five times likely to die in five years if they did not undergo standard treatment (52-55) These results highlight that herbal medicine may complement standard cancer treatment but should not be used in place of evidence-based treatments. An integrative and individualized approach, including both allopathic and herbal medicine, can yield the best and safest results for cancer patients.

II. CONCLUSION

Integrative oncology, the blending of allopathic therapies for cancer and herbal medicine, offers a promising solution to enhance therapeutic efficacy without increasing the toxicities of conventional treatments. Chemotherapy, radiation, immunotherapy, and targeted therapy are very effective but are frequently associated with severe toxicity, drug resistance, and an interference with quality of life. Herbal medicine, however, has bioactive compounds with anticancer activity that include the induction of apoptosis, immune modulation, and inhibition of angiogenesis. As adjuvants to conventional cancer therapies, herbal ingredients such as curcumin, resveratrol, quercetin, and berberine have been shown to improve the potency of conventional treatments, suppress side effects, and counter drug resistance.Clinical evidence substantiates the possible advantages of integrative oncology, indicating better survival and decreased treatment toxicity. Care, though, needs to be taken since substituting conventional treatments with herbal medicines by themselves has been associated with lower survival. Large-scale clinical trials, among other research, is necessary to devise standardized protocols for safe and effective integration of herbal medicine with allopathic treatment.In general, a patient-focused, evidence-based system that includes both mainstream and complementary therapies can improve cancer care, enhance patient health, and maximize treatment outcomes. By bridging the gap between conventional medicine and traditional healing, integrative oncology provides a holistic and promising future direction for cancer treatment strategies.

REFERENCE:

[1]. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660

[2]. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., &Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. https://doi.org/10.3322/caac.21492

[3]. Wang, X., Yang, L., Liu, L., Ran, X., Zhang, H., & Liu, D. (2022). Strategies for overcoming cancer drug resistance: New insights from molecular mechanisms and drug development. Pharmacology & Therapeutics, 239, 108262. https://doi.org/10.1016/j.pharmthera.2021.108262

[4]. Deng, G., Cassileth, B. R., &Yeung, K. S. (2021). Complementary therapies in cancer care: An overview. The Oncologist, 26(1), e1-e11. https://doi.org/10.1002/onco.13555

[5]. Newman, D. J., &Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 1981 to 2019. Journal of Natural Products, 83(3), 770-803. https://doi.org/10.1021/acs.jnatprod.9b01285

[6]. Yuan, H., Ma, Q., Ye, L., &Piao, G. (2016). The traditional medicine and modern medicine from natural products. Molecules, 21(5), 559. https://doi.org/10.3390/molecules21050559

[7]. Cragg, G. M., &Pezzuto, J. M. (2016). Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents. Medical Principles and Practice, 25(Suppl 2), 41–59.

[8]. Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., &Aggarwal, B. B. (2008). Curcumin and cancer: An 'old-age' disease with an 'age-old' solution. Cancer Letters, 267(1), 133–164.

[9]. Prasad, S., Gupta, S. C., Tyagi, A. K., &Aggarwal, B. B. (2014). Curcumin, a component of golden spice: From bedside to bench and back. Biotechnology Advances, 32(6), 1053–1064

[10]. Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., &Kroemer, G. (2015). Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell, 28(6), 690-714.

[11]. Pavlakis, N., &Briasoulis, E. (2017). Molecularly targeted therapies in cancer: The case of kinase inhibitors. The Lancet Oncology, 18(4), 474-485.

[12]. Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.

[13]. Jordan, M. A., & Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nature Reviews Cancer, 4(4), 253-265.

[14]. Baskar, R., Lee, K. A., Yeo, R., &Yeoh, K. W. (2014). Cancer and radiation therapy: Current advances and future directions. International Journal of Medical Sciences, 11(2), 139.

[15]. Delaney, G., Jacob, S., Featherstone, C., & Barton, M. (2005). The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer, 104(6), 1129-1137.

[16]. Durante, M., &Loeffler, J. S. (2010). Charged particles in radiation oncology. Nature Reviews Clinical Oncology, 7(1), 37-43.

[17]. June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., &Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361-1365.

[18]. Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 378(2), 158-168.

[19]. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., ...& Larson, R. A. (2001). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417.

[20]. Hudis, C. A. (2007). Trastuzumab—mechanism of action and use in clinical practice. New England Journal of Medicine, 357(1), 39-51.

[21]. Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13(10), 714-726.

[22]. Osborne, C. K., & Schiff, R. (2011). Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine, 62, 233-247.

[23]. Ali, S., & Coombes, R. C. (2002). Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews Cancer, 2(2), 101-112

[24]. Attard, G., Parker, C., Eeles, R. A., Schroder, F., Tomlins, S. A., Tindall, D. J., ...& de Bono, J. S. (2016). Prostate cancer. The Lancet, 387(10013), 70-82.

[25]. Smith, M. R., Saad, F., Egerdie, B., Sieber, P. R., Tammela, T. L., Ke, C., &Leder, B. Z. (2018). Effects of denosumab on bone mineral density in men receiving androgen deprivation

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar – Apr 2025, pp: 299-308 www.ijprajournal.com ISSN: 2456-4494

therapy for prostate cancer. Journal of Urology, 199(2), 379-386.

[26]. Appelbaum, F. R. (2007). Hematopoietic-cell transplantation at 50. New England Journal of Medicine, 357(15), 1472-1475

[27]. Copelan, E. A. (2006). Hematopoietic stem-cell transplantation. New England Journal of Medicine, 354(17), 1813-1826

[28]. Gyurkocza, B., Sandmaier, B. M., &Appelbaum, F. R. (2010). Graft-versus-host disease: Current therapy and future directions. Frontiers in Immunology, 1, 14.

[29]. van der Zee, J. (2002). Heating the patient: A promising approach? Annals of Oncology, 13(8), 1173-1184

[30]. Dewhirst, M. W., Vujaskovic, Z., Jones, E., & Thrall, D. (2005). Re-setting the biologic rationale for thermal therapy. International Journal of Hyperthermia, 21(8), 779-790.

[31]. Dolmans, D. E., Fukumura, D., & Jain, R. K. (2003). Photodynamic therapy for cancer. Nature Reviews Cancer, 3(5), 380-387.

[32]. Allison, R. R., &Sibata, C. H. (2010). Oncologic photodynamic therapy photosensitizers: A clinical review. Photodiagnosis and Photodynamic Therapy, 7(2), 61-75.

[33]. Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S., & Sung, B. (2013). Curcumin and cancer cell signaling: A dose-dependent effect. Annals of the New York Academy of Sciences, 1271(1), 1–19. https://doi.org/10.1111/j.1749-6632.2012.06780.x

[34]. Jiang, M. C., Yang-Yen, H. F., Yen, J. J., & Lin, J. K. (2019). Curcumin induces apoptosis in immortalized mouse fibroblast NIH 3T3 cells through a reactive oxygen species-dependent mechanism. International Journal of Molecular Sciences, 20(10), 2454. https://doi.org/10.3390/ijms20102454

[35]. Baur, J. A., & Sinclair, D. A. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews Drug Discovery, 5(6), 493–506. https://doi.org/10.1038/nrd2060

[36]. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C., &Pezzuto, J. M. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275(5297), 218–220. https://doi.org/10.1126/science.275.5297.218

[37]. Shukla, Y., & Singh, R. (2011). Resveratrol and cellular mechanisms of cancer prevention. Annals of the New York Academy of Sciences, 1215(1), 1–8. https://doi.org/10.1111/j.1749-6632.2010.05870.x

[38]. Davis, W., Lamson, D. W., &Brignall, M. S. (2009). Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Alternative Medicine Review, 4(5), 304–329.

[39]. Li, Y., Yao, J., Han, C., Yang, J., Chaudhry, M. T., Wang, S., Liu, H., & Yin, Y. (2016). Quercetin, inflammation and immunity. Nutrients, 8(3), 167. https://doi.org/10.3390/nu8030167

[40]. Hollman, P. C., de Vries, J. H., van Leeuwen, S. D., Mengelers, M. J., &Katan, M. B. (1996). Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. The American Journal of Clinical Nutrition, 62(6), 1276–1282. https://doi.org/10.1093/ajcn/62.6.1276

[41]. Yang, C. S., Wang, X., Lu, G., &Picinich, S. C. (2009). Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nature Reviews Cancer, 9(6), 429–439. https://doi.org/10.1038/nrc2641

[42]. Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G., Peracchia, G., &Corti, A. (2006). Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Research, 66(2), 1234–1240. https://doi.org/10.1158/0008-5472.CAN-05-1145

[43]. Li, Y., Yuan, Y., Meeran, S. M., &Tollefsbol, T. O. (2018). Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer

cells. Molecular Cancer, 9(1), 274. https://doi.org/10.1186/1476-4598-9-274

[44]. Sun, Y., Xun, K., Wang, Y., & Chen, X. (2009). A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anti-Cancer Drugs, 20(9), 757–769. https://doi.org/10.1097/CAD.0b013e328330d95b

[45]. Wang, Y., Liu, J., Zhang, J., & Liu, B. (2016). Berberine reverses doxorubicin resistance by inhibiting autophagy through the PTEN/Akt/mTORsignaling pathway in breast cancer. Oncology Reports, 35(6), 3661–3669. https://doi.org/10.3892/or.2016.4734

[46]. Jiang, S., Wang, Q., & Wang, M. (2021). Berberine reverses multidrug resistance of human breast cancer MCF-7/ADR cells via downregulation of P-glycoprotein expression and inhibition of the PI3K/Aktsignaling pathway. Oncology Letters, 21(1), 57. https://doi.org/10.3892/ol.2020.12330

[47]. Zhang, X., Zhao, Y., & Zhang, M. (2020). Berberine inhibits P-glycoprotein in multidrug-resistant leukemia cells via downregulation of NF-κB and MAPK signaling pathways. Biomedicine & Pharmacotherapy, 131, 110673. https://doi.org/10.1016/j.biopha.2020.110673.

[48]. Stan, S. D., Hahm, E. R., Warin, R., & Singh, S. V. (2008). Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Research, 68(18), 7661–7669. https://doi.org/10.1158/0008-5472.CAN-08-1510

[49]. Vyas, A. R., Singh, S. V., &Aggarwal, B. B. (2012). Withaferin A suppresses the epithelial-mesenchymal transition in human breast cancer cells. Oncotarget, 3(6), 585–596. https://doi.org/10.18632/onc

[50]. Zhang, Y., Talalay, P., Cho, C. G., & Posner, G. H. (2006). A major inducer of anticarcinogenic protective enzymes from broccoli: Isolation and elucidation of structure. Proceedings of the National Academy of Sciences, 89(6), 2399–2403. https://doi.org/10.1073/pnas.89.6.2399

[51]. Clarke, J. D., Dashwood, R. H., &Ho, E. (2008). Multi-targeted prevention of cancer by sulforaphane. Cancer Letters, 269(2), 291–304. https://doi.org/10.1016/j.canlet.2008.04.018

[52]. Bisht, R., Joshi, B., & Joshi, H. (2016). Phytomedicine in the treatment of cancer: A health technology assessment. Journal of Clinical and Diagnostic Research, 10(2), ZE10–ZE15. https://doi.org/10.7860/JCDR/2016/17334.7274

[53]. Johnson, S. B., Park, H. S., Gross, C. P., & Yu, J. B. (2018). Use of alternative medicine for cancer and its impact on survival. JAMA Oncology, 4(10), 1375–1381. https://doi.org/10.1001/jamaoncol.2018.2487

[54]. Lee, H. W., Cheon, C., &Ko, S. G. (2024). Safety of the herbal medicine SH003 in patients with solid cancer: A multi-center, single-arm, open-label, dose-escalation phase I study. Integrative Cancer Therapies, 23, 15347354241293451. https://doi.org/10.1177/15347354241293451

[55]. Oh, S., Kim, K. Y., & Lee, J. H. (2024). Fucoidan-induced anti-inflammatory and anti-cancer effects in advanced cancer patients. Marine Drugs, 22(1), 15. https://doi.org/10.3390/md22010015